Press Releases
Date Title and Summary View
Aug 16, 2013 NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it has signed an agreement with a major pharmaceutical company for the exclusive right to negotiate a royalty-bearing U.S. license for a product to be developed for the treatment of Autism and Schizophrenia. Pursuant to the ex...
Aug 16, 2013 Company to Hold Update Conference Call Today, August 16, 2013 at 10:00 a.m. ET NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it has received positive survival results from interim preclinical tests for the Company's compound, RE-024, for the treatmen...
Aug 7, 2013 NEW YORK--(BUSINESS WIRE)-- Retrophin, Inc. (RTRX), a pharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, today announced that Steven R. Eby, R.Ph has begun serving as a consultant to the Company a...
May 8, 2013 New York, NY (May 8, 2013) – Retrophin, Inc. (OTCQB: RTRX) today announced that it has named Marc L. Panoff, CPA, MBA as Chief Financial Officer and Chief Accounting Officer, effective May 20. Retrophin is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of debilitating and often life-t...
Apr 25, 2013 New York, NY (April 25, 2013) – Retrophin, Inc. (OTCQB: RTRX), a pharmaceutical company focused on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently no viable patient options, today announced that it has named Horacio Plotkin, M.D. as Chief Medical...
Apr 8, 2013 New York, NY (April 8, 2013) – Retrophin, Inc. (OTCQB: RTRX), a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options, today announced that it sponsored the Seventh International N...
Mar 11, 2013 New York, NY (March 11, 2013) – Retrophin, Inc. (OTCQB: RTRX), a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options, today announced positive results from a series of in vitro and in vivo experi...
Mar 8, 2013 New York, NY (March 8, 2013) – Retrophin, Inc. (OTCQB: RTRX), a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options, today announced that Martin Shkreli, founder and chief executive officer, will...
Feb 12, 2013 New York, NY (February 12, 2013) – Desert Gateway (OTCPK: RTRX), the parent company of Retrophin, Inc., a biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, today announced it has entered definitive agreements with institutional investors in connection with a private pla...
Feb 4, 2013 New York, NY (February 4, 2013) – Retrophin (OTCQB: RTRX), a biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, today announced that Martin Shkreli, Founder & Chief Executive Officer, will be presenting at the 15th Annual BIO CEO & Investor Conference,...
Page: FirstPrevious ...
13
NextLast
= add release to Briefcase